Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988 Feb;11(2):141-4.
doi: 10.1016/s0272-6386(88)80199-9.

Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation

R D Gordon  1 , A G Tzakis, S Iwatsuki, S Todo, C O Esquivel, J W Marsh, A Stieber, L Makowka, T E Starzl
Affiliations
Clinical Trial

Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation

R D Gordon et al. Am J Kidney Dis. 1988 Feb.

Abstract

Experience with the use of Orthoclone OKT3 monoclonal antibody for the treatment of acute cellular rejection in a series of 130 human orthotopic liver transplantations is reviewed. Treatment was highly effective in reversing rejection, in reducing the rate of retransplantation, and in lowering patient mortality. OKT3 was also useful for cyclosporine sparing in patients with poor renal function, hypertension, or CNS toxicity. There was a significant incidence of opportunistic infection associated with the use of OKT3.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Actuarial graft survival in group 1 and group 2 patients treated with Orthoclone OKT3 compared with historical controls treated with high dose steroids and/or polyclonal ALG. Survival of group 2 grafts is significantly better than control and group 1 grafts (P < .01).
Fig 2
Fig 2
Current protocol for use of Orthoclone OKT3 in the management of liver transplant recipients. Prophylactic use of OKT3 in high-risk patients needs also to be considered.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gordon RD, Shaw BW, Jr, Iwatsuki S, et al. Indications for liver transplantation in the cyclosporine era. Surg Clin North Am. 1986;66:541–556. - PubMed
    1. Shaw BW, Jr, Gordon RD, Iwatsuki S, et al. Hepatic re-transplantation. Transplant Proc. 1985;17:264–271. - PMC - PubMed
    1. Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet. 1967;124:301–318. - PMC - PubMed
    1. Cosimi AB, Colvin R, Burton R, et al. Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. N Engl J Med. 1981;305:308–314. - PubMed
    1. Cosimi AB, Burton R, Colvin R, et al. Treatment of acute allograft rejection with OKT3 monoclonal antibody. Transplantation. 1981;32:535–539. - PubMed

Publication types

MeSH terms